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Abbreviations:  
BOO: bladder outlet obstruction 
Cx43: connexin 43 
Cx45: connexin 45 
bFGF: basic fibroblast growth factor  
ZT: zeitgeber time 
2 
POD: post-operative day 
DMEM: Dulbecco's modified Eagle's medium 
FCS: fetal calf serum 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
ERK: extracellular signal regulated kinase 
pERK: phospho-extracellular signal regulated kinase 
Fwd: Forward  
Rev: Reverse  
RT-PCR: reverse transcription-polymerase chain reaction 
BSMC: bladder smooth muscle cells  











Purpose: Basic fibroblast growth factor (bFGF) is a candidate causative factor of 
detrusor overactivity in bladder outlet obstruction (BOO), through up-regulation of 
connexin 43 (Cx43), a gap-junction protein. This study addresses the transcriptional 
and behavioral implications of this axis. 
Materials and Methods: Cx43 and Cx45 mRNA expression was assessed by real-
time RT-PCR in the bladder of a rat BOO model and in cultured rat bladder smooth 
muscle cells (BSMC) with and without bFGF treatment. The involvement of the 
ERK1/2-AP-1 pathway was evaluated by immunofluorescent study and a promoter-
reporter assay in BSMC. The effect of bFGF on micturition behavior was measured 
in unrestrained rats under a 12 h light/dark cycle, using a controlled release system 
from gelatin hydrogels fixed on the bladders. The expression of ERK1/2 and Cx43 
protein was assessed by western blotting of rat bladder protein. 
Results: Cx43, but not Cx45, mRNA expression was increased in the bladder of 
the BOO model and in BSMC treated with bFGF. PD98059, a MEK inhibitor, 
blocked the stimulatory effect of bFGF on Cx43 protein expression and promoter 
activity, which was also decreased by mutation or deletion of an AP-1 cis-element of 
the Cx43 promoter. In vivo application of bFGF on the bladder increased the urinary 
frequency during the latter half of the dark phase, i.e., the late active phase of rats 
(F=5.1; P<0.05, by two-way ANOVA). The expression of pERK1/2 and Cx43 
protein was elevated in the bladder. 
Conclusions: The ERK1/2-AP-1-Cx43 axis could be a potential therapeutic target 




Overactivity of the obstructed bladder is a highly prevalent and recognized 
clinical condition.
1
 In an experimental rat model, Saito et al reported that 
unrestrained rats with BOO under conditions of a 12 h light/12 h dark cycle, showed 
increased urinary frequency in the dark and active phase.
2
 However, the mechanism 
underlying this phenomenon has not yet been elucidated clinically or experimentally. 
Cx43 and Cx45 are major gap junction proteins in the bladder. Up-regulation of 
Cx43 has been implicated in detrusor overactivity in rats with BOO, in association 
with increased intercellular transmission of electrical and chemical excitation 
through gap junctions.
3-5
 Bladders retrieved from BOO rats show hypersensitivity on 
a cystometrogram, and this is blocked by a gap junction inhibitor.
6
 
Basic FGF is a multifunctional growth factor, known to be elevated in urine under 
various clinical pathological conditions of the bladder, including voiding 
dysfunction.
7,8 We have previously shown that bFGF is produced by the urothelium 
of the obstructed rat bladder and that Cx43 protein expression is up-regulated via 
ERK1/2 activation in BSMC. The elevation of Cx43 causes bladder overactivity in 
muscle strip tests, corresponding to increased micturition frequency in a 
cystometrogram under anesthesia.
5
 However, in this previous study, the precise 
mechanism of Cx43 protein up-regulation by bFGF was not fully investigated. In 
addition, the behavioral implications of these phenomena are unknown. 
Transcriptional control is one of the most important steps in the regulation of 
Cx43 protein, although many steps are involved in the pathway from DNA to protein 
in its tissue dependent expression.
9
 Several factors are reported to regulate Cx43 
5 
promoter activity, such as transcriptional factors Sp1
 
and AP-1, signaling molecules 




Since AP-1 is known to be a major target of stretch-induced gene expression in 
BSMC, and is activated by pERK1/2,
14,15
 and the AP-1 cis-element is regulated by 
bFGF,
16
 we hypothesized that the bFGF-ERK pathway regulates the expression of 
Cx43 in the obstructed bladder via AP-1. In vitro, the transcriptional regulation of 
Cx43 promoter activity by bFGF was studied in cultured BSMC. In vivo, we 
investigated the impact of BOO on Cx43 and Cx45 mRNA expression. We also 
investigated the effect of bFGF on micturition behavior using our original system, in 
which bFGF incorporated in gelatin hydrogels is control-released by gel degradation 
over 1 week. We applied this system, which was originally used to accelerate tissue 
regeneration in various organs,
17-20










BSMC were isolated from 9-week-old female Sprague-Dawley rats (Japan SLC 
Inc, Shizuoka, Japan) using a procedure described previously.
17,21
 Cells after two 
passages were seeded at 6 × 10
4
 cells/2 ml in 6-well plates for RNA extraction and 1 
× 10
4




Seven-week-old female Sprague-Dawley rats weighing 170 to 190 g were 
purchased from Japan SLC Inc. Animals were treated in accordance
 
with NIH 
animal care guidelines and all animal experiments were
 
approved by the Kyoto 
University Animal Experiment Committee. 
 
Rat bladder outlet obstruction model 
 
Partial BOO was created in nine rats using methods previously described.
5,17
 
Briefly, a longitudinally incised 2 mm-long PE200 polyethylene catheter (BD 
Intramedic, Sparks, MD) was placed around the proximal urethra. Three sham-
operated rats underwent similar procedures, but the catheter was removed before 
closing the abdominal incision. After 5, 7, and 14 days in the BOO group (n=3 for 
each day) and 14 days in the sham group, bladders were removed and weighed. All 
7 
samples were immediately placed in RNAlater solution (Ambion, Austin, TX). 
 
Behavioral effect of bFGF on rat bladders using gelatin hydrogels as release 
carriers 
 
A gelatin hydrogel, containing human recombinant bFGF (Kaken Pharmaceutical 
Co. Tokyo, Japan) (0 or 10 g/site), was fixed to the bladder of unrestrained rats 
(n=8 for each group) as previously described.
5,17
 The rats were maintained under the 
conditions of a 12 h light/12 h dark cycle (8 am light on [ZT=0] and 8 pm light off 
[ZT=12]) throughout the experiment. This included a 7-day adaptation period before 
the operation with free access to water and food. In six animals in each group, 
urinary frequency was measured for 11 days under the same conditions upon an 
electronic balance system as described previously.
22
 Two rats in each group were 




Whole cell lysates from bladder tissue were lysed with radio-immunoprecipitation 
assay buffer containing protease inhibitors. The protein content of the cell lysates 
was measured using the BioRad Protein Assay Kit. Cell
 
lysates were resolved by 
sodium dodecylsulfate polyacrylamide electrophoresis and transferred to an 
Immobilon-P membrane (Millipore, Bedford, MA). The membranes were incubated
 
with antibodies against pERK1/2 (1:1000, CST, Beverly MA), ERK1/2 (1:1000, 




internal control. After incubation with HRP-conjugated anti-rabbit secondary 
antibodies (Pierce, Rockford, IL), immunoreactive proteins were visualized using a 
Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). Each 
band was quantified by densitometry using Image J 1.42q software (NIH, Bethesda, 
MD). 
 
RNA extraction and real-time RT-PCR 
 
BSMC were treated with bFGF 10 g/ml for 36 h following serum depletion in 
DMEM containing 0.5% FCS for 48 h. Total RNA was extracted from BSMC and 
the bladders of the BOO model, and mRNA expression of Cx43 and Cx45 was 
evaluated by real-time RT-PCR (n=4). Total RNA extraction and cDNA synthesis 
were carried out using the RNeasy Mini Kit and SuperScript First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA) as described previously.
17
 The 
primers used were as follows: rat Cx43 Fwd: CCATCCAAAGACTGCGGAT and 
Rev: GTAATTGCGGCACGAGGAA; Cx45 Fwd: CAGAGCCAACCAAAACCCA 
and Rev: GAAAGCCCACCTCAAACACA; and -actin Fwd: 
GAAGCTGTGCTATGTTGCCCT and Rev: TTCTGCATCCTGTCAGCAATG. 
These primers were designed using Primer Express 2.0 software (Applied 
Biosystems, Foster City, CA). Quantitative real-time PCR was performed in 25-l 
reactions containing SYBR Green PCR Master Mix using the 7500 Fast Real-Time 
PCR System (Applied Biosystems). Reaction mixtures were denatured at 95°C for 
10 min, followed by 40 PCR cycles. Each cycle consisted of the following three 
steps: 94°C for 15 s, 57°C for 15 s, and 72°C for 1 min. Each sample was 
9 
normalized against an internal 18s ribosomal RNA control
19
 in BSMC and -actin 
was used in the BOO model. 
 
Immunofluorescent study 
BSMC were treated with bFGF 10 g/ml with and without PD98059 (Calbiochem, 
San Diego, CA), the MEK inhibitor, 5 M for 48 h following serum depletion in 
DMEM containing 0.5% FCS for 48 h. Cells were washed twice and fixed with 4% 
paraformaldehyde, followed by heating in 0.01 M citrate buffer (pH 6.0) for 20 min 
for antigen retrieval. Samples were incubated with antibody against Cx43 (1:100) in 
Canget Signal solution A (Toyobo, Osaka, Japan) for 12 h at 4°C. The binding was 
detected using biotinylated anti-rabbit secondary antibody and Alexa Fluor 555-





The mouse pGL-2-Cx43 promoter-reporter (pCx43 -1686/+165-Luc), constructed 
by Dr. Lye SJ,
23
 was a kind gift from Dr. Jian Yao (University of Yamanashi, 
Yamanashi, Japan), and the appropriate negative and control constructs, pGL-2 basic 
and pRL-TK respectively, were purchased from Promega (Madison, WI). Site 
directed mutagenesis deletion and truncation of the AP-1 site of pCx43 were 
performed using a mutagenesis basal kit (Takara Bio, Shiga, Japan) according to the 
protocol. Promoter constructs were transfected into rat BSMC as follows. BSMC 
were transfected with 240 ng pCx43-Luc and 1 ng pTK-RL using Fugene6 (Roche, 
10 
Indianapolis, IN) in DMEM-10% FCS for 24 h. Cells were treated with bFGF (0, 10, 
and 50 ng/ml; n=3 for each concentration) in DMEM-0.5% FCS for 24 h. To further 
investigate the effect of factors mediating effects downstream of bFGF, cells were 
treated with 50 ng/ml bFGF with or without 5 M PD98059 (n=6). Lysates were 
harvested 48 h post-transfection and luciferase activity was measured using the dual 




Data were analyzed with one-way ANOVA in multiple comparisons and Mann-
Whitney U-test for the relative mRNA expression and luciferase assay using SPSS 
ver.11.0.1J software (SPSS inc., Chicago, IL). For comparing the urinary frequency 
with and without bFGF, t-test and two-way repeated measures ANOVA were used. 




Cx43 mRNA expression is increased in the BOO model and in BSMC treated with 
bFGF 
 
In the bladder of the BOO model, Cx43 mRNA expression was increased after the 
operation compared with sham-operated controls, in parallel with an increase in 
bladder weight (Figs. 1A, B). There was no increase in Cx45 mRNA expression. In 
cultured BSMC, Cx43 mRNA expression was also significantly increased with 
stimulation of bFGF for 36 h (Fig. 1C), with no increase in expression of Cx45. 
 
Basic FGF up-regulates Cx43 transcription via the ERK1/2-AP-1 pathway 
 
Immunofluorescence showed increased Cx43 protein expression in BSMC with 
bFGF treatment, and this was blocked by the ERK1/2 inhibitor, PD98059 (Fig. 2A), 
replicating our previous results by immunoblots.
5
 The influence of transcriptional 
regulation of Cx43 protein expression by the bFGF-ERK1/2 pathway was assessed 
by a promoter-reporter assay using BSMC. Cx43 promoter activity was significantly 
up-regulated upon stimulation of bFGF (50 ng/ml) (Fig. 2B), and this was blocked 
by PD98059 (Fig. 2C). 
We then focused on two putative AP-1 sites ‘TGAGTCA’ and ‘TGACTCA’ 
located at 43 and 995 base pairs, respectively, upstream from TSS of the Cx43 
promoter, which are evolutionally conserved among humans, rats and mice.
10,11
 The 
distal site was considered unrelated to the effect of bFGF, as truncation mutants of 
12 
this site were still responsive to bFGF stimulation (data not shown). Mutation and 
deletion of the other proximal AP-1 site (Fig. 2D) blocked the effect of bFGF on 
Cx43 promoter activity (Fig. 2E).  
 
Basic FGF induces urinary frequency in the late active phase of unrestrained rats 
 
Unrestrained rats treated with 10 g/site bFGF in the bladder showed significantly 
increased urinary frequency in the latter half of the dark phase, i.e., the late active 
phase of rats, compared with rats without bFGF stimulation on POD 8 (17.7 ± 2.5 
vs.10.8 ± 1.5; P<0.05, t-test; Figs. 3A, B). In diachronic analysis, rats with bFGF 
stimulation urinated more frequently than those without bFGF only in this late active 
phase (P<0.05, by two-way repeated measures ANOVA; Figs. 3C, D). Western 
blotting showed that the expression of pERK1/2 and Cx43, especially the 
phosphorylated forms, was increased in bladder tissue with bFGF stimulation at ZT 
12 and 24 (Fig. 4). There were no significant differences in micturition volume and 




The present study demonstrates that bFGF up-regulates Cx43 transcription in 
BSMC via the ERK1/2-AP-1 pathway, and that this mechanism may underlie Cx43 
overexpression in the obstructed bladder. Such phenomena might be associated with 
increased urinary frequency during the active phase in rats with BOO.  
A major finding in this study is the differential transcriptional regulation of Cx43 
and Cx45 by bFGF. Basic FGF is a candidate signaling molecule for pathological 
conditions of the bladder, as it has been reported to be elevated in the urine from 
patients with voiding dysfunction.
7,8
 In the rat BOO model, although it can be 
difficult to detect bFGF in urine,
24
 we have reported its up-regulation in the 
urothelium.
5,17
 In cultured BSMC, bFGF up-regulated Cx43, but not Cx45, which is 
the other major gap junction protein in the bladder, replicating our findings in an in 
vivo release model.
5
 This finding is particularly interesting because similar 
differential modulation of gap junction proteins was also observed in the bladder of 
the BOO model. If the hypersensitivity in the BOO model is related to increased gap 
junction function by bFGF, our results suggest that this is more likely to be 
associated with Cx43 than with Cx45. 
 Another major finding was the identification of the ERK-AP-1 pathway for 
transcriptional regulation of Cx43 mRNA by bFGF. As reported in our previous 
study, an increase of Cx43 protein by bFGF was blocked by PD98059, the ERK 
inhibitor. Since this ERK-dependency was also observed in promoter activity, and 
AP-1 is a known downstream transcription factor of ERK, we investigated the 
involvement of two putative evolutionally conserved AP-1 sites in the Cx43 
14 
promoter. A promoter-reporter assay using deleted, mutated, or truncated constructs 
suggested that the proximal AP-1 site could be involved in the response to bFGF. 
Although the proximal AP-1 site in the Cx43 promoter has been implicated in 
transcriptional activity,
9-11
 no upstream signaling has been reported thus far, and our 
findings illustrate the physiological role of AP-1 for Cx43 regulation. 
Interestingly we found that bFGF, by itself, could induce altered micturition 
behavior typically observed in the BOO model. Basic FGF increased daytime 
urinary frequency in unrestrained rats, as reported previously in the BOO model.
2
 
Our bFGF control-release model has several common features with the short-term 
BOO model, representing the compensated phase of BOO, in which up-regulation of 
bFGF has been reported.
5,17,25
 In these control-release and short-term BOO models, a 
proliferation of SMC, a decrease in the collagen I/III ratio, and an increase in Cx43 
protein expression have been reported.
5,17,25
 Our results could extend such 
biochemical similarity to behavioral aspect. 
 One unexpected finding in our study was the unaffected urinary frequency during 
the sleeping phase, because clinically, nocturia has been recognized as a sign and a 
major problem related to BOO, typically seen in the elderly with prostate 
hypertrophy, and it is included in the International Prostate Symptom Score. Despite 
elevated pERK and Cx43 levels at ZT 12 and 24, the urinary frequency of the rats 
remained undisturbed during the sleeping phase. Although urinary frequency is one 
of the major symptoms in BOO,
1
 the distinction between daytime and nighttime 
frequency (i.e., nocturia) has been recently emphasized.
2,26,27
 While there is an 
association of nocturia with benign prostatic hyperplasia, recent epidemiological 
studies suggest that the etiology of nocturia is not always related to BOO, and is far 
15 
more diverse and multi-factorial, including the sleep-awake cycle and urine 
production by the kidneys.
27
 Therefore, unaffected micturition frequency during the 
sleeping phase observed in the bFGF control-release model and the BOO model,
2
 
may suggest that the early phase of BOO does not affect nighttime urinary frequency, 
and this may not be contradictory with clinical observations in patients with voiding 
problems.  
We observed an increased expression of Cx43 protein and its phosphorylated 
form, which has been associated with stabilized gap junction function,
5
 on POD 7.
 
This corresponded to elevated pERK1/2 levels, which could be interpreted as the 
accumulative effect of bFGF that continues until around POD 7.
18
 At approximately 
POD 7, urinary frequency of the rats reaches a peak, while the decrease in frequency 
by POD 11 could be associated with the loss of bFGF release from the gelatin 
hydrogel;
18
 this suggests that the effect of bFGF on the bladder is reversible. This 
reversible alteration in urinary frequency is a major difference between our model 
and the BOO model, which is associated with complex mechanical over-distention 
and ischemic change.
28
 In the long-term BOO model, defined as a decompensated 
state associated with chronic ischemic change, bFGF is not elevated anymore,
25
 and 
Cx43 has an altered cellular localization.
28,29
 On the other hand, relief from BOO 
does not return urinary frequency on a cystometrogram to normal levels after 28 
days from relief,
29
 although Cx43 mRNA expression returns to normal levels by this 
time. Such complex features of the BOO model have made it difficult for researchers 
to analyze its pathogenesis mechanistically. Therefore, our control-release system is 
a valuable model that enables a more accurate determination of the in vivo effect of 
bFGF on Cx43 expression. 
16 
Finally, although our study demonstrates an effect of bFGF on Cx43 regulation, 
there may be other factors associated with the pathological state of bladder 
dysfunction regulating the expression of Cx43,
30
 because bFGF could not be 
elevated in every patients with such diseases.
8
 Our results indicate that various other 
AP-1 regulating factors could be possible candidates for Cx43 up-regulation, and 
such factors could be candidate targets for innovative therapies against bladder 




The present findings may explain the relationship between the elevation of bFGF 
in the obstructed bladder and the associated lower urinary tract symptoms. They also 
suggest that the ERK1/2-AP-1-Cx43 axis could be a potential therapeutic target for 
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Fig. 1 Cx43 mRNA expression is increased in the BOO model and in BSMC treated 
with bFGF, but the expression of Cx45 is not. A: Bladder weights of sham-operated 
rats on POD 14 and BOO model rats retrieved at 5, 7, and 14 days postoperatively 
(n=3 for each point). B: Relative mRNA expressions of Cx43 and Cx45 in the same 
animals. For relative expression, each value for shams was set as 1. *P<0.05 
compared with shams. C: Relative mRNA expressions of Cx43 and Cx45 in rat 
BSMC treated with 10 ng/ml of bFGF for 36 h following 48 h of serum depletion 
(n=4 for each point, ***P<0.001, **P<0.005 compared with controls by ANOVA). 
Each value at 0 h was set as 1. Error bars indicate s.d. 
 
Fig. 2. Basic FGF stimulates Cx43 promoter activity through the ERK1/2-AP-1 
pathway in rat BSMC. A: Immunofluorescence shows that inhibition of ERK1/2 by 
PD98059 blocks up-regulation of Cx43 protein by bFGF. B: Promoter-reporter assay 
shows dose dependent activation of the Cx43 promoter. C: PD98059 blocks Cx43 
promoter activation by bFGF.  D: The conserved putative AP-1 site of the Cx43 
promoter. E: Alterations of the AP-1 site block Cx43 promoter activation with bFGF. 
The value of WT without bFGF was set as 1. *P<0.05, **P<0.01 and ***P<0.005 
by ANOVA. Error bars indicate s.d. 
 
Fig. 3. Basic FGF increases urinary frequency during the late active phase in 
unrestrained rats. A: Daily micturition pattern of unrestrained rats (n=12) before the 
operation. B: A significant difference in the urinary frequency can be noted between 
22 
rats with and those without control-released bFGF during the latter half of the dark 
phase, i.e., the active phase of rats, on POD 8. C: Urinary frequency in the latter half 
of the light phase, i.e., the sleeping phase of rats, is not affected by bFGF throughout 
the study period. D: Controlled release of bFGF significantly increased urinary 
frequency during the late active phase. Note that this difference diminishes by POD 
11. †P<0.05 by two-way ANOVA. Error bars indicate s.e.m. 
 
Fig. 4. Basic FGF up-regulates pERK1/2 and Cx43 protein expression. Expression 
of pERK and Cx43 in the bladder at ZT 12 and 24 on POD 7 was assessed by 
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